RxDoctor Payments Data

Taylor Ellis

Family · San Antonio, TXNPI 1538602370

Payments from drug & device makers

$7,975in general payments, 2019–2025

Across 461 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • Lilly USA, LLC$723
  • AstraZeneca$683
  • Amgen$446
  • GSK$318
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,975100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,975 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$17,141
Medicare patients
136
Services billed
1,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide40$39,017
Janumet XrSitagliptin Phos/Metformin Hcl27$24,880
JanuviaSitagliptin Phosphate18$18,477
WegovySemaglutide11$16,215
ArexvyRsvpref3 Antigen/As01e/Pf24$7,332
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$3,000
Levothyroxine Sodium188$2,455
Atorvastatin Calcium214$2,334
Rosuvastatin Calcium129$1,906
Mometasone Furoate12$1,896
SynthroidLevothyroxine Sodium29$1,347
Omeprazole55$1,166
Bupropion XlBupropion Hcl23$974
Valsartan29$902
Metoprolol Succinate49$774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet Xr, Januvia$256$43,35745 claims
Lilly USA, LLCMounjaro$723$39,01740 claims
Novo NordiskWegovy$1,636$16,21511 claims
GSKArexvy$318$7,33224 claims
AbbVieSynthroid$1,606$1,34729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →